NCT01931787

CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

A Pilot Clinical Trial of CPI-613 in Patients With Relapsed or Refractory Small Cell Lung Carcinoma (SCLC)

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Wake Forest University Health Sciences · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This pilot clinical trial studies CPI-613 (6,8-bis\[benzylthio\]octanoic acid) in treating patients with relapsed or refractory small cell lung cancer. CPI-613 may interfere with the growth of tumor cells and may be an effective treatment for small cell lung cancer.

Detailed description

PRIMARY OBJECTIVES: I. To evaluate the safety and anti-cancer activities in patients with relapsed or refractory small cell lung cancer (SCLC) who have failed 1 or 2 lines of chemotherapy. OUTLINE: Patients receive CPI-613 intravenously (IV) over 2 hours on days 1 and 4 of weeks 1-3. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 2 months.

Conditions

• Recurrent Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	6,8-bis(benzylthio)octanoic acid	Given IV

Timeline

• Start date: 2013-10-01
• Primary completion: 2015-12-01
• Completion: 2015-12-01
• First posted: 2013-08-29
• Last updated: 2018-07-03

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study